Enanta Pharmaceuticals (NASDAQ:ENTA) Given Buy Rating at HC Wainwright

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $20.00 price target on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 49.59% from the company’s previous close.

Several other equities research analysts also recently issued reports on ENTA. Wall Street Zen downgraded Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Rodman & Renshaw initiated coverage on Enanta Pharmaceuticals in a research note on Thursday, March 26th. They set a “buy” rating and a $20.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Monday, April 20th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.29.

Enanta Pharmaceuticals Stock Performance

ENTA opened at $13.37 on Tuesday. The firm’s fifty day moving average is $13.32 and its two-hundred day moving average is $13.65. The firm has a market cap of $388.80 million, a PE ratio of -5.16 and a beta of 0.97. Enanta Pharmaceuticals has a twelve month low of $6.43 and a twelve month high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.01. The business had revenue of $17.16 million during the quarter, compared to analysts’ expectations of $17.03 million. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative return on equity of 64.04%. Equities analysts forecast that Enanta Pharmaceuticals will post -1.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Meeder Asset Management Inc. bought a new stake in Enanta Pharmaceuticals in the 4th quarter valued at approximately $32,000. Seven Fleet Capital Management LP bought a new position in shares of Enanta Pharmaceuticals during the 4th quarter worth approximately $36,000. Strs Ohio bought a new position in shares of Enanta Pharmaceuticals during the 4th quarter worth approximately $50,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Enanta Pharmaceuticals by 333.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 2,758 shares in the last quarter. Finally, Quarry LP acquired a new stake in shares of Enanta Pharmaceuticals in the third quarter valued at approximately $81,000. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.